Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
Author
Kennedy, Nicholas A.
Warner, B
Johnston, E L
Flanders, L
Hendy, P
Ding, N S
Harris, R
Fadra, A S
Basquill, C
Lamb, C A
Cameron, F L
Murray, C D
Parkes, M
Gooding, I
Ahmad, Tariq
Gaya, D R
Mann, S
Lindsay, J O
Gordon, J
Satsangi, J
Hart, A
McCartney, S
Irving, P
Lees, C W
Date
2016-02-19Journal
Alimentary pharmacology & therapeuticsType
Journal ArticleMeta-Analysis
Systematic review
Publisher
WileyDOI
10.1111/apt.13547Rights
Archived with thanks to Alimentary Pharmacology & Therapeutics. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Metadata
Show full item recordAbstract
Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for more data to establish the relapse rates following treatment cessation.